Melbourne, May 6, 2009 (ABN Newswire) - Leading developer of RNA interference (RNAi)-based therapeutics Benitec Limited (ASX:BLT)(PINK:BNIKF) announced today that Dr John Zaia had presented an update on City of Hope's HIV human stem cell study at an international conference in San Diego, USA.
Findings from the trial were presented at the International Society of Cell Therapy conference held in San Diego May 3-6 2009 by John A. Zaia M.D. the Aaron D. and Edith Miller Endowed Chair for Gene Therapy and chair of virology, Beckman Research Institute of City of Hope. City of Hope is a biomedical research and treatment facility located northeast of Los Angeles.
The presentation was entitled "Current status of Gene Therapy for HIV/AIDS" and was an update and confirmation of the previously presented encouraging results.
"These study results show that we can deliver gene modified cells which have the potential to limit the HIV infection. If we can continue to develop this approach and successfully apply it to other AIDS patients, then genetic therapy for HIV could become a reality", said Sue MacLeman, CEO Benitec Limited.
About Benitec Limited
Benitec Limited (ASX:BLT) (PINK:BNIKF) holds a dominant position in expressed RNA interference (RNAi)-based human therapeutics, with a transformational platform technology supported by a robust and extensive intellectual property portfolio. Benitec is leveraging this platform to develop and build a pipeline of expressed RNAi therapeutics focusing on treatment and alleviation of cancer and infectious disease. With strong global partnerships and committed scientific and clinical investigators, Benitec Ltd aims to deliver a range of novel RNAi-based therapeutics to the clinic in partnership with the pharmaceutical industry.
Contact
BENITEC LTD Sue MacLeman Chief Executive Officer Tel: +61-437-211-200
Benitec Limited
){kind=link}